NextGen restructures management as it gears up for assay launches
This article was originally published in Clinica
Executive Summary
Biomarker specialist NextGen Sciences (Ann Arbor, Michigan) has appointed Neal Siegel to the new role of director of assay development. Dr Siegel, who previously worked at Sword Diagnostics and Abbott Labs, will oversee assay delivery, validation and quality control at NextGen. The company has also appointed Glenn Barney vice-president of business development. Formerly of Decision Biomarkers, Mr Barney will help drive sales growth across all NextGen products. He will also lead the firm’s marketing activities, and will be joined by the new director of marketing, Hiroshi Saito, who joins from internet and digital marketing agency Optiem. The new appointments come as NextGen prepares to launch two new biomarker assays markets in the first half of this year; one is a human plasma assay targeting several oncology disease areas, and the other is a human cerebrospinal fluid assay for central nervous system disorders.